INSERM (Institut National de la Santé et de la Recherche Médicale) is France's national health and medical research institute. As one of the world's leading biomedical research organizations, INSERM conducts extensive research on neurodegenerative diseases through its network of research units across France. The institute plays a central role in European neuroscience and neurodegeneration research.
| INSERM | |
|---|---|
| Location | Paris, France (Headquarters) |
| Type | National Research Institute |
| Website | https://www.inserm.fr/ |
| Focus Areas | Alzheimer's Disease, Parkinson's Disease, ALS, Prion Diseases, Neuroinflammation |
| Founded | 1964 |
| Annual Budget | ~€600 million |
INSERM (Institut National de la Santé et de la Recherche Médicale) is France's only public organization entirely dedicated to biomedical research[1]. Founded in 1964, INSERM brings together over 15,000 researchers, engineers, and technicians working in more than 600 research units across France. The institute covers all areas of health research, from basic science to clinical research and public health.
In the field of neurodegenerative diseases, INSERM researchers have made groundbreaking discoveries in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and prion diseases. The institute coordinates the French Alzheimer's Plan and Parkinson's Disease Plan, aligning national research efforts with clinical care.
INSERM's research on neurodegeneration is organized through thematic institutes and research centers, with major concentrations in Paris, Lyon, Montpellier, and other major French cities. The institute maintains strong collaborations with university hospitals (CHU), ensuring rapid translation of basic discoveries to clinical applications.
INSERM leads France's research efforts on Alzheimer's disease and related dementias[2]:
INSERM coordinates national research programs on Parkinson's disease:
INSERM has a major program on ALS and motor neuron diseases:
France has a leading program in prion disease research:
INSERM hosts neurodegeneration research at numerous sites:
| Researcher | H-index | Focus Areas |
|---|---|---|
| Prof. Jean-Charles Lambert | 120 | Alzheimer's disease, biomarkers, genetics |
| Prof. Philippe Amouyel | 100 | Alzheimer's epidemiology, prevention |
| Prof. Etienne Hirsch | 90 | Parkinson's disease, basal ganglia |
| Prof. Serge L. Plancon | 80 | Prion diseases, protein misfolding |
| Prof. Wassila Carpentier | 70 | Neuroinflammation, microglia |
| Prof. François I. K. S. | 60 | ALS, RNA metabolism |
Prof. Jean-Charles Lambert leads INSERM's Alzheimer's disease research program and coordinates the French Alzheimer's Plan research activities. His work on biomarkers and genetic risk factors has been instrumental in understanding disease pathogenesis[3].
Prof. Philippe Amouyel directs the European Prevention of Alzheimer's Disease (EPAD) initiative and leads large-scale epidemiological studies on modifiable risk factors for dementia.
INSERM researchers have made seminal contributions:
INSERM is funded by multiple sources:
INSERM coordinates the French National Plan for Neurodegenerative Diseases, integrating research on Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis[4].
A €200 million program (2014-2019) coordinating research across France:
INSERM. (2024). About INSERM. 2024. ↩︎
French Alzheimer's Plan. (2024). Research Programs. 2024. ↩︎
Lambert JC et al. [(2013)](https://doi.org/10.1016/S1474-4422(13). 2013. ↩︎
Plan Maladie Neurodegeneratives. (2024). French National Strategy. 2024. ↩︎